Ki67 targeted strategies for cancer therapy

被引:227
作者
Yang, C. [1 ]
Zhang, J. [1 ]
Ding, M. [1 ,2 ]
Xu, K. [1 ,2 ]
Li, L. [1 ]
Mao, L. [1 ,2 ]
Zheng, J. [1 ]
机构
[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China
[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China
关键词
Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;
D O I
10.1007/s12094-017-1774-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 50 条
  • [31] Clinical validity and clinical utility of Ki67 in early breast cancer
    Kreipe, Hans
    Harbeck, Nadia
    Christgen, Matthias
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [32] Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer
    Li, Pan
    Xiao, Zhi-Tao
    Braciak, Todd A.
    Ou, Qing-Jan
    Chen, Gong
    Oduncu, Fuat S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 696 - 702
  • [33] Prognostic Significance of the Ki67 Scoring Categories in Breast Cancer Subgroups
    Niikura, Naoki
    Masuda, Shinobu
    Kumaki, Nobue
    Tang Xiaoyan
    Terada, Mizuho
    Terao, Mayako
    Iwamoto, Takayuki
    Oshitanai, Risa
    Morioka, Toru
    Tuda, Banri
    Okamura, Takuho
    Saito, Yuki
    Suzuki, Yasuhiro
    Tokuda, Yutaka
    CLINICAL BREAST CANCER, 2014, 14 (05) : 323 - 329
  • [34] KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach
    William JF Green
    Graham Ball
    Geoffrey Hulman
    Catherine Johnson
    Gerry Van Schalwyk
    Hari L Ratan
    Daniel Soria
    Jonathan M Garibaldi
    Richard Parkinson
    Joshua Hulman
    Robert Rees
    Desmond G Powe
    British Journal of Cancer, 2016, 115 : 236 - 242
  • [35] Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients
    Haroon, Saroona
    Hashmi, Atif Ali
    Khurshid, Amna
    Kanpurwala, Muhammad Adnan
    Mujtuba, Shafaq
    Malik, Babar
    Faridi, Naveen
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (07) : 4353 - 4358
  • [36] Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy
    Bubendorf, L
    Sauter, G
    Moch, H
    Schmid, HP
    Gasser, TC
    Jordan, P
    Mihatsch, MJ
    JOURNAL OF PATHOLOGY, 1996, 178 (04) : 437 - 441
  • [37] Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
    Jiang, Peng
    Jia, Mingzhu
    Hu, Jing
    Huang, Zhen
    Deng, Ying
    Lai, Li
    Ding, Shanshan
    Hu, Zhuoying
    ONCOTARGETS AND THERAPY, 2020, 13 : 10841 - 10850
  • [38] Ki67: biological intertumor variance versus variance of assay
    Kreipe, H.
    PATHOLOGE, 2018, 39 : 272 - 277
  • [39] Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients
    Gerring, Zac
    Pearson, John F.
    Morrin, Helen R.
    Robinson, Bridget A.
    Harris, Gavin C.
    Walker, Logan C.
    HISTOPATHOLOGY, 2015, 67 (04) : 538 - 547
  • [40] Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
    Claudette Falato
    Julie Lorent
    Edneia Tani
    Eva Karlsson
    Paul K. Wright
    Jonas Bergh
    Theodoros Foukakis
    Breast Cancer Research and Treatment, 2014, 147 : 407 - 414